K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.08
    +0.05 (+0.45%)

    Market Cap: $218.69M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(13/26)
    Avg Surprise
    +1361.01%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.86
    Range$-1.53 - $-0.56
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-1.34-56.4%
    60d ago$-1.30-50.9%
    30d ago$-1.30-50.9%
    7d ago$-0.79+8.4%
    Current$-0.86
    Revenue Consensus
    $14M
    Range$350000 - $20M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-2.20
    Range$-2.88 - $-1.60
    5 analysts
    Revenue Consensus
    $-718560
    Range$-15218420 - $4M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.20---
    Sep 26EST
    		-$-0.86---
    Jun 26
    		$-1.45$-1.25-16.00%Miss-90.8%
    Mar 26
    		$-1.21$-0.73-66.23%Miss-133.4%
    Dec 25
    		$-0.86$-0.45-91.11%Miss+24.6%
    Sep 25
    		$-0.18N/A+83.78%Beat+87.2%
    Jun 25
    		$-0.76$-1.13+32.74%Beat+39.2%
    Mar 25
    		$3.62$0.01+36100.00%Beat+399.2%
    Dec 24
    		$-1.14$-0.43-166.98%Miss+14.9%
    Sep 24
    		$-1.41$-1.28-10.16%Miss-6.0%
    Jun 24
    		$-1.25$-1.25+0.00%Beat+1.6%
    Mar 24
    		$-1.21$-1.33+9.02%Beat+4.0%
    Dec 23
    		$-1.34$-1.37+2.19%Beat-22.9%
    Sep 23
    		$-1.33$-1.35+1.48%Beat-44.6%
    Jun 23
    		$-1.27$-1.35+5.93%Beat-12.4%
    Mar 23
    		$-1.26$-1.14-10.53%Miss-24.8%
    Dec 22
    		$-1.09$-1.10+0.91%Beat-263.3%
    Sep 22
    		$-0.92$-1.26+26.98%Beat-5.7%
    Jun 22
    		$-1.13$-1.07-5.61%Miss-68.7%
    Mar 22
    		$-1.01$-0.86-17.44%Miss-48.5%
    Dec 21
    		$-0.30N/A+67.39%Beat+38.8%
    Sep 21
    		$-0.87$-0.72-20.83%Miss-45.0%
    Jun 21
    		$-0.67$-0.65-3.08%Miss-8.1%
    Mar 21
    		$-0.68$-0.58-17.24%Miss+86.7%
    Dec 20
    		$-0.49$-0.57+14.04%Beat-
    Sep 20
    		$-0.60$-0.59-1.69%Miss-
    Jun 20
    		$-0.62$-0.67+7.46%Beat-
    Mar 20
    		$-5.11$-0.80-538.75%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.99EV/EBITDA-13.05x
    Price/FCF-4.52xFCF Yield-22.10%
    Profitability
    Profit Margin0.00%Operating Margin-656.00%
    ROE-17.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio21.96xQuick Ratio21.96x
    Trading Statistics
    Beta1.01Avg Volume221.57K
    52-Week High$22.5552-Week Low$9.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.06
    SMA 20$10.82
    SMA 50$10.78
    SMA 200$13.78
    EMA 10$11.03
    EMA 20$10.88
    EMA 50$10.84
    EMA 200$12.43

    MACD

    Line: 0.15Signal: 0.11Hist: 0.05

    ADX

    ADX: 24.8+DI: 21.2-DI: 15.0

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down24.0
    PSAR$10.14

    Bollinger Bands

    Upper Band$11.65
    Lower Band$9.99
    %B Position1538%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    53.2

    Momentum Oscillators

    Stoch %K64.9
    Stoch %D69.7
    Williams %R-37.1
    ROC (10d)5.7%
    Momentum0.60
    CCI (20d)49.8
    MFI (14d)46.3

    Volatility Measures

    ATR (14d)$0.54(4.9%)
    StdDev (20d)0.42
    Hist Vol63.6%(High)

    Volume Flow

    VWAP$11.01
    OBV16.6M
    AD Line16.5M
    CMF (20d)0.234

    Volume Metrics

    Avg Vol (20d)224.9K
    Vol Ratio0.8x
    VWMA (20d)$10.75

    Pivot Points

    R3$11.85
    R2$11.50
    R1$11.27
    Pivot Point$10.92
    S1$10.69
    S2$10.34
    S3$10.11

    Advanced Oscillators

    TSI7.10
    Ultimate Osc59.1
    KST40.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$367,000$385,000$14.26M$18.17M$211.25M$3.04M$388,000$37,000$83,000$143,000$8,000
    Cost of Revenue$0$0$400,000$0$0$0$332,000$0$0$0$247,000$0
    Gross Profit$0$367,000$385,000$14.26M$18.17M$211.25M$3.04M$388,000$37,000$83,000$143,000$8,000
    Operating Expenses$30.94M$26.24M$29.66M$29.65M$57.98M$59.21M$56.30M$59.05M$50.48M$48.57M$46.60M$43.29M
    R&D$22.33M$16.10M$17.91M$19.52M$43.50M$48.71M$45.63M$49.23M$40.52M$38.26M$37.49M$34.14M
    SG&A$8.61M$10.15M$11.74M$10.13M$14.48M$10.50M$10.66M$9.82M$9.96M$10.31M$9.11M$9.15M
    Operating Income$-30,937,000$-25,877,000$-29,270,000$-15,384,000$-39,817,000$152.04M$-53,254,000$-58,657,000$-50,439,000$-48,483,000$-46,455,000$-43,280,000
    Interest Income$2.29M$2.33M$4.02M$6.93M$7.12M$6.79M$6.52M$5.79M$5.38M$5.81M$3.76M$3.91M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-28,710,000$-23,708,000$-24,975,000$-8,704,000$-32,918,000$158.49M$-45,726,000$-52,956,000$-45,257,000$-43,114,000$-40,243,000$-39,440,000
    Income Tax Expense$0$0$-1,514,000$-1,424,000$-2,222,000$10.04M$300,000$0$0$0$0$0
    Net Income$-28,710,000$-23,708,000$-23,461,000$-7,280,000$-30,696,000$148.45M$-46,026,000$-52,956,000$-45,257,000$-43,114,000$-40,243,000$-39,440,000
    EBITDA$-30,595,000$-25,640,000$-28,597,000$-15,242,000$-39,668,000$152.05M$-51,341,000$-57,872,000$-49,983,000$-48,304,000$-43,417,000$-42,796,000
    EBIT$-30,997,000$-26,043,000$-28,997,000$-15,637,000$-40,038,000$151.70M$-52,245,000$-58,749,000$-50,635,000$-48,920,000$-43,999,000$-43,347,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KROS

    News

    ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS

    ADAR1 Capital Management LLC has purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) during the second quarter, acquiring 246,818 shares valued at approximately $2.64 million. This makes ADAR1 Capital Management LLC the owner of about 1.24% of Keros Therapeutics' stock. Other institutional investors have also adjusted their holdings, and the article also details recent insider stock sales, Keros Therapeutics' financial performance, and current analyst ratings.

    MarketBeat•8/26/26•
    Somewhat-Bearish

    Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

    Keros Therapeutics (KROS) reported a significant Q2 2026 loss and zero revenue, shifting investment focus heavily to its pipeline drug rinvatercept. While the company has a cash runway into H1 2028, its high valuation, intense competition in Duchenne muscular dystrophy, and dependence on a single lead asset raise concerns. Analysts suggest caution, given the current risk-reward profile and neutral short-term outlook.

    TradingView•8/24/26•
    Bearish

    Keros Therapeutics (NASDAQ:KROS) Raised to Sell at Wall Street Zen

    Keros Therapeutics (NASDAQ:KROS) was upgraded by Wall Street Zen from a "strong sell" to a "sell" rating, though the overall analyst consensus remains "Hold" with a target price of $20.50. The company reported a quarterly loss of $1.45 per share, missing estimates, and its shares opened at $11.03, near the lower end of its 12-month range. Insider sales totaled nearly $145,000 in the past 90 days, while institutional investors hold 71.56% of the stock.

    MarketBeat•8/24/26•
    Somewhat-Bearish

    Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

    Lorena Raquel Lerner, an insider at Keros Therapeutics (NASDAQ:KROS), sold 3,568 shares for $36,714.72 to cover tax withholding obligations related to vested equity awards, reducing her ownership by 11.46%. The company is facing weak financial performance with a recent quarterly loss and its stock trading near a 12-month low. Analyst ratings are mixed, with a consensus "Hold" and an average target price of $20.50.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

    Annita Tanini, VP at Keros Therapeutics, sold 1,224 shares of KROS stock worth $12,594.96 to cover tax withholding obligations on August 18th, 2026, reducing her stake by 2.64%. This insider sale comes amidst weak financial results, with the company missing earnings estimates and analysts projecting a full-year loss of $5.16 per share. Despite institutional ownership of 71.56% and an average analyst target of $20.50, the stock is trading significantly lower at $10.95, with mixed analyst ratings.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About KROS

    Does KROS pay dividends?
    Keros Therapeutics Inc (KROS) does not currently pay a regular dividend.
    What is KROS's market cap?
    Keros Therapeutics Inc (KROS) has a market capitalization of $218.69M with a current stock price of $11.08.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In